Hims & Hers Health Inc. (HIMS) saw its stock soar 6.94% on Monday, following the company's announcement of key leadership appointments aimed at strengthening its focus on quality, safety, and regulatory compliance.
The telehealth firm appointed Deb Autor, a former deputy commissioner at the U.S. Food and Drug Administration (FDA), to its board of directors. Autor brings over 30 years of experience in pharmaceutical quality, compliance, regulatory programs, and consumer protection. During her tenure at the FDA, she oversaw inspections, criminal investigations, and international operations for the agency.
Additionally, Hims & Hers named Janet Stevens as its Global Head of Quality & Safety. Stevens has spent her entire career in pharmaceutical quality assurance, operations, and engineering. She previously served as the Chief Quality Officer at Hillrom, where she helped the company achieve top-quartile results in global quality regulations.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。